Posts Tagged ‘Tim Cannon’
“Should Runners Be Worried About Colon Cancer?,” Runner’s World, September 19, 2025
While endurance running is widely celebrated for its health benefits, a trailblazing study led by Tim Cannon, MD, Sheridan Director of the Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova Schar Cancer, reveals a surprising link to colon cancer risk. Featured in Runner’s World, the research opens important conversations around screening…
Read More“Are Marathons and Extreme Running Linked to Colon Cancer?,” New York Times, August 19, 2025
Running marathons or endurance races is often seen as a hallmark of peak fitness. However, a groundbreaking new study led by Inova oncologist Tim Cannon, MD, Sheridan Director, Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova Schar Cancer, reveals a surprising prevalence of precancerous colon growths among extreme runners. Recently featured…
Read MoreInova Schar Cancer joins pioneering national effort to transform cancer care through ARPA-H’s ADAPT Program
Fairfax, VA – May 27, 2025 – Inova Schar Cancer is proud to participate in a groundbreaking national effort to transform how cancer is treated, through a major award from the Advanced Research Projects Agency for Health (ARPA-H). The initiative—ADvanced Analysis for Precision cancer Therapy (ADAPT)—aims to change the way cancer treatment decisions are made…
Read More